

**Clinical Policy: Daratumumab (Darzalex),
Daratumumab/Hyaluronidase-fihj (Darzalex Faspro)**

Reference Number: CP.PHAR.310

Effective Date: 07.01.17

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Daratumumab (Darzalex[®]) is a CD38-directed cytolytic antibody. Daratumumab/hyaluronidase-fihj (Darzalex Faspro[™]) is a combination of daratumumab and hyaluronidase, an endoglycosidase.

FDA Approved Indication(s)

Darzalex and Darzalex Faspro are indicated for the treatment of adult patients with multiple myeloma (MM):

- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory MM who have received at least one prior therapy
- In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for ASCT
- In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for ASCT
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- As monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory MM who have received one to three prior lines of therapy

Darzalex is additionally indicated for the treatment of adult patients with MM:

- In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a PI

Darzalex Faspro is additionally indicated for the treatment of adult patients with:

- MM in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant
- MM in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- MM in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a PI

- High-risk smoldering MM as monotherapy
- Light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed adult patients

Limitation(s) of use: Darzalex Faspro is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Darzalex and Darzalex Faspro are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Multiple Myeloma (must meet all):

1. Diagnosis of MM;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age $\geq$ 18 years;
4. Darzalex or Darzalex Faspro is prescribed in one of the following ways (a, b, or c):
 - a. Primary therapy (i, ii, or iii):
 - i. Ineligible for ASCT and in combination with one of the following (a or b):
 - a) lenalidomide* and dexamethasone;
 - b) bortezomib*, melphalan, and prednisone;
 - c) bortezomib*, lenalidomide*, and dexamethasone;
 - ii. Eligible for ASCT in combination with one of the following (a, b, c, or d):
 - a) bortezomib*, thalidomide*, and dexamethasone;
 - b) bortezomib*, lenalidomide*, and dexamethasone;
 - c) bortezomib*, cyclophosphamide, dexamethasone;
 - d) carfilzomib*, lenalidomide*, and dexamethasone;
 - iii. As monotherapy for high-risk smoldering MM as evidenced by at least two of the following (a, b, or c):
 - a) Serum monoclonal protein level > 2 g/dL;
 - b) Involved-to-uninvolved serum-free light chain ratio > 20 ;
 - c) Bone marrow plasma cells $> 20\%$;
 - b. Subsequent therapy (i, ii, iii, iv, or v):
 - i. In combination with dexamethasone and either lenalidomide*, bortezomib* (with or without cyclophosphamide), carfilzomib*, Venclexta[®]*, or Xpovio[®]* after ≥ 1 prior therapy;
 - ii. In combination with carfilzomib*, pomalidomide*, and dexamethasone;
 - iii. In combination with pomalidomide* and dexamethasone after ≥ 1 prior therapies including both of the following (a and b):
 - a) An immunomodulatory agent (e.g., thalidomide*, lenalidomide*);
 - b) A PI (e.g., ixazomib*, bortezomib*, carfilzomib*);

- iv. As monotherapy after ≥ 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent;
 - v. In combination with Tecvayli[®], and member has received or has documented intolerance to ≥ 1 prior line of therapy (*see Appendix B for examples*) that include both of the following (a and b):
 - a) One proteasome inhibitor (e.g., bortezomib, Kyprolis[®], Ninlaro[®]);
 - b) One immunomodulatory agent (e.g., lenalidomide, pomalidomide, thalidomide);
 - c. Maintenance therapy for symptomatic MM as a single agent or in combination with lenalidomide for transplant candidates (off-label);
- *Prior authorization may be required.*
- 5. Request meets one of the following (a or b):*
 - a. Dose does not exceed the maximum indicated regimen in section V;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
- *Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:**Medicaid/HIM/ICHRA** – 12 months**Commercial** – 6 months or to the member's renewal date, whichever is longer**B. Systemic Light Chain Amyloidosis (must meet all):**

- 1. Diagnosis of systemic light chain amyloidosis;
 - 2. Prescribed by or in consultation with an oncologist or hematologist;
 - 3. Age ≥ 18 years;
 - 4. Darzalex/Darzalex Faspro is prescribed in one of the following ways (a, b, c, d, or e):
 - a. In combination with bortezomib*, cyclophosphamide, and dexamethasone;
 - b. In combination with lenalidomide* and dexamethasone for relapsed or refractory previously treated disease;
 - c. As a single agent for relapsed or refractory disease after ≥ 1 prior therapy (e.g., bortezomib*, lenalidomide*) (*off-label***);
 - d. As a single agent for newly diagnosed disease if member has Mayo stage IIIb disease and no significant neuropathy (*off-label***);
 - e. In combination with Venclexta* for t(11;14) in relapsed or refractory previously treated disease;
- *Prior authorization may be required.*
- **If request is for off-label use, refer to NCCN for dosing regimen.*
- 5. Request meets one of the following (a or b):*
 - a. Dose does not exceed the maximum indicated regimen in section V;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
- *Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:**Medicaid/HIM/ICHRA** – 12 months**Commercial** – 6 months or to the member's renewal date, whichever is longer

C. Acute Lymphoblastic Leukemia (off-label) (must meet all):

1. Diagnosis of T-cell acute lymphoblastic leukemia (T-ALL);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Member has relapsed or refractory disease;
4. Prescribed as part of a daratumumab containing regimen (e.g., daratumumab, vincristine, pegaspargase or calaspargase, doxorubicin, and prednisone or dexamethasone);
5. Dose is within FDA maximum limit for any FDA-approved indication in Section V or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

D. HIV-Related Plasmablastic Lymphoma (off-label) (must meet all):

1. Diagnosis of HIV-related plasmablastic lymphoma;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Request is for first-line therapy;
4. Prescribed concurrently as a component of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin);
5. Dose is within FDA maximum limit for any FDA-approved indication in Section V or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

E. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy**A. All Indications in Section I (must meet all):**

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Darzalex or Darzalex Faspro for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed the maximum indicated regimen in section V;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 6 months or to the member's renewal date, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information*Appendix A: Abbreviation/Acronym Key*

ASCT: autologous stem cell transplant

FDA: Food and Drug Administration

MM: multiple myeloma

NCCN: National Comprehensive Cancer Network

PI: proteasome inhibitor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

and may require prior authorization.		
Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<i>Agents with FDA-approved dosing for MM</i>		
Ninlaro® (ixazomib)	4 mg PO on days 1, 8, and 15 of every 28-day treatment cycle	See dosing regimen
bortezomib (Velcade®)	1.3 mg/m ² SC or IV; frequency of administration varies based on specific use	
Kyprolis® (carfilzomib)	20 mg/m ² , 27 mg/m ² , and/or 56 mg/m ² IV; frequency of administration varies based on specific use	
Revlimid® (lenalidomide)	10 mg or 25 mg PO QD; dose and frequency of administration vary based on specific use	
Thalomid® (thalidomide)	100 mg, 200 mg, or 400 mg PO QD; dose and frequency of administration vary based on specific use	
<i>MM: regimens containing proteasome inhibitors and immunomodulatory agents (examples – NCCN)</i>		
bortezomib / lenalidomide (Revlimid®) or pomalidomide or Thalomid (thalidomide) / dexamethasone	Varies	Varies
Kyprolis (carfilzomib – weekly or twice weekly) / dexamethasone	Varies	Varies
Kyprolis (carfilzomib) / lenalidomide (Revlimid) / dexamethasone	Varies	Varies
Ninlaro (ixazomib) / lenalidomide (Revlimid) / dexamethasone	Varies	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity
- Boxed warning(s): none reported

Appendix D: General Information

- The National Comprehensive Cancer Network compendium makes the following recommendation for Darzalex Faspro (category 2A): For multiple myeloma, may be used as a single agent or in combination with other systemic therapies where intravenous daratumumab is recommended.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Darzalex	MM in combination with lenalidomide or	<u>Weeks 1 to 8:</u> 16 mg/kg IV weekly	See dosing regimen -

Drug Name	Indication	Dosing Regimen	Maximum Dose
	pomalidomide (4-week cycle dosing regimens) and low-dose dexamethasone and for monotherapy	<u>Weeks 9 to 24:</u> 16 mg/kg IV every 2 weeks <u>Weeks 25 onwards until disease progression:</u> 16 mg/kg IV every 4 weeks	Package Insert, Table 1
	MM in combination with bortezomib, melphalan and prednisone ([VMP], 6-week cycle dosing regimen)	<u>Weeks 1 to 6:</u> 16 mg/kg IV weekly <u>Weeks 7 to 54:</u> 16 mg/kg IV every 3 weeks <u>Weeks 55 onwards until disease progression:</u> 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 2
	MM in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)	<u>Induction</u> <u>Weeks 1 to 8:</u> 16 mg/kg IV weekly <u>Weeks 9 to 16:</u> 16 mg/kg IV every 2 weeks <u>Consolidation</u> <u>Weeks 1 to 8:</u> 16 mg/kg IV every 2 weeks	See dosing regimen - Package Insert, Table 3
	MM in combination with bortezomib and dexamethasone (3-week cycle dosing regimen)	<u>Weeks 1 to 9:</u> 16 mg/kg IV weekly <u>Weeks 10 to 24:</u> 16 mg/kg IV every 3 weeks <u>Weeks 25 onwards until disease progression:</u> 16 mg/kg IV every 4 weeks	See dosing regimen - Package Insert, Table 4
	MM in combination with carfilzomib and dexamethasone (4-week cycle dosing regimen)	<u>Week 1:</u> 8 mg/kg IV days 1 and 2 <u>Weeks 2 to 8:</u> 16 mg/kg IV weekly <u>Weeks 9 to 24:</u> 16 mg/kg IV every 2 weeks <u>Weeks 25 onwards until disease progression:</u>	See dosing regimen - Package Insert, Table 5

Drug Name	Indication	Dosing Regimen	Maximum Dose
		16 mg/kg IV every 4 weeks	
Darzalex Faspro	MM in combination with lenalidomide or pomalidomide and dexamethasone (4-week cycle) or as monotherapy	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 8: weekly</u> <u>Weeks 9 to 24: every 2 weeks</u> <u>Weeks 25 onwards until disease progression: every 4 weeks</u>	See dosing regimen - Package Insert, Table 1
	MM in combination with bortezomib, melphalan and prednisone ([VMP]; 6-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 6: weekly</u> <u>Weeks 7 to 54: every 3 weeks</u> <u>Weeks 55 onwards until disease progression: every 4 weeks</u>	See dosing regimen - Package Insert, Table 2
	MM in combination with bortezomib, thalidomide, and dexamethasone ([D-VTd]; 4-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Induction: <u>Weeks 1 to 8: weekly (total of 8 doses)</u> <u>Weeks 9 to 16: every 2 weeks (total of 4 doses)</u>	See dosing regimen - Package Insert, Table 3

Drug Name	Indication	Dosing Regimen	Maximum Dose
		Consolidation: <u>Weeks 1 to 8 (following ASCT): every 2 weeks (total of 4 doses)</u>	
	MM in combination with bortezomib and dexamethasone ([D-Vd]; 3-week cycle)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 9: weekly (total of 9 doses)</u> <u>Weeks 10 to 24: every 3 weeks (total of 5 doses)</u> <u>Weeks 25 onwards until disease progression: every 4 weeks</u>	See dosing regimen - Package Insert, Table 6
	MM in combination with bortezomib, lenalidomide, and dexamethasone ([D-VRd]; 4-week cycle) for patients eligible for ASCT	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes Induction: <u>Weeks 1 to 8: weekly (total of 8 doses)</u> <u>Weeks 9 to 16: every 2 weeks (total of 4 doses)</u> Consolidation: <u>Weeks 1 to 8 (following ASCT): every 2 weeks (total of 4 doses)</u>	See dosing regimen - Package Insert, Table 4
	MM in combination with bortezomib, lenalidomide, and dexamethasone ([D-VRd]; 3-week cycle) for patients ineligible for ASCT	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 6: weekly (total of 6 doses)</u> <u>Weeks 7 to 24: every 3 weeks (total of 6 doses)</u> <u>Weeks 25 onwards until disease progression: every 4 weeks</u>	See dosing regimen - Package Insert, Table 5

Drug Name	Indication	Dosing Regimen	Maximum Dose
	High-risk smoldering MM	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 8: weekly (total of 8 doses)</u> <u>Weeks 9 to 24: every 2 weeks (total of 8 doses)</u> <u>Weeks 25 onwards until diagnosis of MM or a maximum of 3 years: every 4 weeks</u>	See dosing regimen - Package Insert, Table 7
Darzalex Faspro	Light chain amyloidosis – in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCD)	1,800 mg daratumumab -30,000 units hyaluronidase SC into the abdomen over approximately 3 to 5 minutes <u>Weeks 1 to 8: weekly (total of 8 doses)</u> <u>Weeks 9 to 24: every 2 weeks (total of 8 doses)</u> <u>Weeks 25 onwards until disease progression or a maximum of 2 years: every 4 weeks</u>	See dosing regimen - Package Insert, Table 8

VI. Product Availability

Drug Name	Availability
Daratumumab (Darzalex)	Single-dose vials: 100 mg/5 mL, 400 mg/20 mL
Daratumumab/hyaluronidase-fihj (Darzalex Faspro)	Single-dose vial: providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase/15 mL

VII. References

1. Darzalex Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; April 2025. Available at <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf>. Accessed April 15, 2026.
2. Darzalex FasPro Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; February 2026. Available at <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf>. Accessed April 15, 2026.
3. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed May 5, 2026.

4. National Comprehensive Cancer Network. Multiple Myeloma Version 5.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed May 5, 2026.
5. National Comprehensive Cancer Network Systemic Light Chain Amyloidosis Version 2.2026. Available at https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed May 5, 2026.
6. Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. *Blood*. 2017; 130(7): 900-902.
7. Palladini G, Kastiris E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood*. 2020;136(1):71-80. doi: 10.1182/blood.2019004460.
8. National Comprehensive Cancer Network Pediatric Acute Lymphoblastic Leukemia Version 1.2026. Available at https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf. Accessed May 5, 2026.
9. National Comprehensive Cancer Network Acute Lymphoblastic Leukemia Version 1.2026. Available at https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed May 5, 2026.
10. Dimopoulos MA, Voorhees PM, Schjesvold F, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. *N Engl J Med*. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029.
11. National Comprehensive Cancer Network B-Cell Lymphomas Version 3.2026. Available at https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed May 5, 2026

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9145	Injection, daratumumab, 10 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
3Q 2022 annual review: per NCCN added additional combination regimens for MM primary therapy in those eligible for ASCT, for MM subsequent therapy added combination use with Xpovio and clarified use as monotherapy is allowable only after at least 3 prior lines of therapy or if double-refractory to PI and immunomodulatory agent; references reviewed and updated.	04.28.22	08.22
Template changes applied to other diagnoses/indications.	09.21.22	
3Q 2023 annual review: per NCCN added off-label use for maintenance therapy for symptomatic MM as a single agent for	04.14.23	08.23

Reviews, Revisions, and Approvals	Date	P&T Approval Date
transplant candidates; clarified for systemic light chain amyloidosis use is as a single agent for relapsed or refractory disease; references reviewed and updated.		
3Q 2024 annual review: per NCCN Compendium for systemic light chain amyloidosis added off-label use as a single agent for newly diagnosed disease if member has significant neuropathy or has Mayo stage IIIb disease; added off-label use for T-cell acute lymphoblastic leukemia; for MM as subsequent therapy added combination use with dexamethasone and Venclexta; for MM maintenance therapy added combination use with lenalidomide; references reviewed and updated.	05.06.24	08.24
RT4: for Darzalex Faspro added to FDA approved indications new use for MM in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant.	08.12.24	
3Q 2025 annual review: for systemic light chain amyloidosis added NCCN Compendium supported use in combination with lenalidomide and dexamethasone; for MM added NCCN Compendium supported use as subsequent therapy in combination with carfilzomib, pomalidomide, and dexamethasone; references reviewed and updated.	04.14.25	08.25
RT4: for Darzalex Faspro added to FDA approved indications new use for high-risk smoldering MM as monotherapy; for light chain amyloidosis removed statement regarding accelerated approval to reflect conversion to full approval; modified approval durations for Medicaid/HIM to 12 months, for Commercial '6 months or to the member's renewal date, whichever is longer'.	12.02.25	
RT4: for Darzalex Faspro added to FDA approved indications new use for MM in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for ASCT.	02.27.26	
3Q 2026 annual review: added NCCN Compendium supported use for MM in combination with Tecvayli; added additional use for systemic light chain amyloidosis in combination with Venclexta, clarified use in combination with lenalidomide and dexamethasone should be for relapsed/refractory previously treated disease, and for use as single agent therapy in newly diagnosed disease corrected to require no significant neuropathy; added criteria set for HIV-related plasmablastic lymphoma; added ICHRA line of business; references reviewed and updated.	05.05.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence.

Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.